致电 400-821-0776或联系我们

致电 400-821-0776 或联系我们

购物车

创新药研发的全面伙伴
留言
客服微信
客服邮箱
order@sanyoubio.com
客服邮箱
客服电话
400-821-0776
客服电话
创新药研发
的全面伙伴

致电400-821-0776
或联系我们

购物车

肝细胞癌
背景介绍
产品清单
实验数据
背景介绍
疾病定义
肝癌(Liver cancer)仍然是一个全球性的健康挑战,其发病率在全球范围内不断增高,预计到2025年,肝癌的患病人数将达到100万人。肝细胞癌(Hepatocellular carcinoma,HCC)是最常见的一种肝癌类型,约占所有肝癌病例中的90%。乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)感染是HCC发生发展的主要外源性风险因素,但在一些西方国家中,与代谢综合征或者糖尿病相关的非酒精性脂肪肝(Non-alcoholic steatohepatitis)正在成为更常见的风险因素。
流行病学
肝癌的全球负担沉重。根据2020年数据统计,全球有90.57万人被诊断患有肝癌,83.02万人死于肝癌,肝癌是46个国家癌症死亡的第三大原因,也是全球90个国家癌症致死的第五大原因。近日,世界卫生组织下属的国际癌症研究机构(IARC/WHO)研究人员在《Journal of Hepatology》发表了最新研究成果“Global burden of primary liver cancer in 2020 and predictions to 2040”。研究人员预计,到2040年全球肝癌的新确诊病例和死亡人数可能会增加55%。
全球肝癌负担
肝细胞癌的发病机制
HCC的病理生理学是一个复杂的多步骤过程。80%的HCC 发生在肝硬化患者中,各种因素的相互作用是肝细胞恶性转化和HCC发展早期阶段的起源。这些因素包括遗传倾向、病毒和非病毒风险因素之间的相互作用、细胞微环境和各种免疫细胞,以及潜在慢性肝病的严重程度。改变的微环境是肿瘤的关键促成特征,并且已知参与恶性进展的所有阶段。
HCC的发生发展过程
产品清单
肝细胞癌的治疗靶点涉及多个方面,包括肿瘤细胞的生长和分化、血管生成、免疫调节以及肿瘤微环境等。以下是一些常见的肝癌治疗靶点:
三优生物为研究肝细胞癌的科学家们提供了一系列高质量的试剂产品,涵盖了该疾病的关键靶点。产品包括重组蛋白、抗体以及过表达细胞株,为研究人员提供了强大的工具来深入探究肝细胞癌的发病机制和治疗策略。
实验数据

案例数据-重组蛋白

Human GPC3 / Glypican-3, His Tag
货号:PHA134    表达系统:HEK293
Human GPC3 / Glypican-3(S495A, S509A), Fc Tag
货号:PHD650    表达系统:HEK293

A: Immobilized Human GPC3 / Glypican-3, His Tag at 2 μg/mL can bind Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab), EC50=0.003621μg/mL.

B:Immobilized Human GPC3 / Glypican-3(S495A, S509A), Fc Tag at 2 μg/mL can bind Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab), EC50=0.05101 μg/mL.

数据案例-参比抗体

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)
货号:CHA050    表达系统:CHO

A: Huh-7 cells were stained with anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS.

B:HEP3B cells were stained with anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS.

A:The endocytosis ratio codrituzumab by HuH-7 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 40%at antibody concentration of 1 nM.

B:Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab) induced ADCC activity was evaluated using human GPC3 CHOS Cell. The max Lysis rate was approximately 30%.

数据案例-过表达细胞株

Human GPC3 / Glypican-3 CHO Cell Line(Monoclonal)
货号:XHB597    宿主细胞:CHO
Human GPC3 / Glypican-3 HEK293 Cell Line(Monoclonal)
货号:XHB598    宿主细胞:HEK293

A:Human GPC3 / Glypican-3 CHO Cell Line were stained with Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS.

B:Human GPC3 / Glypican-3 HEK293 Cell Line were stained with Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS.

联系我们

电话: 400-821-0776

隐私政策

沪ICP备15044189号-4

社交媒体